AGILON HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.83 USD | -2.62% |
|
-5.85% | -61.51% |
| 04-22 | Citigroup Starts agilon health With Neutral Rating, $6 Price Target | MT |
| 03-06 | Barclays Initiates Agilon Health With Underweight Rating, Price Target is $5 | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 10,629 | 6,647 | 5,096 | 2,039 | - | - |
| Enterprise Value (EV) 1 | 9,637 | 6,194 | 5,027 | 1,863 | 1,875 | 2,039 |
| P/E ratio | -24.8 x | -62.1 x | -19.6 x | -13.9 x | -25.2 x | -42.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.8 x | 2.45 x | 1.18 x | 0.32 x | 0.26 x | 0.21 x |
| EV / Revenue | 5.26 x | 2.29 x | 1.16 x | 0.29 x | 0.24 x | 0.21 x |
| EV / EBITDA | -250 x | 1,457 x | -52.9 x | -40.9 x | 66.9 x | 23.8 x |
| EV / FCF | -62.3 x | -42.4 x | -29.2 x | -18.2 x | -93.9 x | -302 x |
| FCF Yield | -1.61% | -2.36% | -3.42% | -5.51% | -1.07% | -0.33% |
| Price to Book | 9.89 x | 6.39 x | 7.82 x | 3.58 x | 4.04 x | - |
| Nbr of stocks (in thousands) | 393,655 | 411,855 | 406,041 | 411,057 | - | - |
| Reference price 2 | 27.00 | 16.14 | 12.55 | 4.960 | 4.960 | 4.960 |
| Announcement Date | 03/03/22 | 01/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,218 | 1,834 | 2,708 | 4,316 | 6,396 | 7,954 | 9,526 |
| EBITDA 1 | - | -38.62 | 4.251 | -95 | -45.51 | 28.03 | 85.81 |
| EBIT 1 | - | -394 | -120.4 | -231.9 | -181.4 | -123.3 | -122.5 |
| Operating Margin | - | -21.49% | -4.45% | -5.37% | -2.84% | -1.55% | -1.29% |
| Earnings before Tax (EBT) 1 | - | -404.6 | -105.7 | -194.5 | -161.7 | -86.16 | -73.49 |
| Net income 1 | -60.05 | -406.5 | -106.6 | -262.6 | -145.8 | -81.86 | -49.34 |
| Net margin | -4.93% | -22.17% | -3.93% | -6.08% | -2.28% | -1.03% | -0.52% |
| EPS 2 | -19.54 | -1.090 | -0.2600 | -0.6400 | -0.3558 | -0.1969 | -0.1175 |
| Free Cash Flow 1 | - | -154.7 | -146.2 | -172 | -102.6 | -19.97 | -6.75 |
| FCF margin | - | -8.44% | -5.4% | -3.99% | -1.6% | -0.25% | -0.07% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 18/03/21 | 03/03/22 | 01/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 458.6 | 462.9 | 653.4 | 670.1 | 694.9 | 689.8 | 1,136 | 1,149 | 1,216 | 1,056 | 1,605 | 1,600 | 1,628 | 1,566 | 2,057 |
| EBITDA 1 | -14.02 | -26.69 | 12.03 | 7.496 | -4.653 | -10.62 | 23.86 | 10.26 | -5.777 | -137.1 | 17.31 | -4.201 | -18.89 | -39.86 | 47.95 |
| EBIT 1 | -35.6 | -47.87 | -0.743 | -21.05 | -29.52 | -69.12 | 6.261 | -29.82 | -48.97 | -164.3 | -14.96 | -39.3 | -55.97 | -71.22 | 6.3 |
| Operating Margin | -7.76% | -10.34% | -0.11% | -3.14% | -4.25% | -10.02% | 0.55% | -2.6% | -4.03% | -15.56% | -0.93% | -2.46% | -3.44% | -4.55% | 0.31% |
| Earnings before Tax (EBT) 1 | -36.74 | -57.25 | 0.655 | -20.46 | -29.94 | -55.94 | 14.2 | -15.72 | -30.27 | -166.9 | -5.532 | -24.82 | -44.64 | -85.64 | 32.91 |
| Net income 1 | -35.84 | -56.72 | 1.23 | -20.65 | -30.67 | -56.47 | 16.02 | -16.75 | -31.44 | -230.4 | -7.67 | -29.25 | -40.06 | -62.64 | 26.33 |
| Net margin | -7.82% | -12.25% | 0.19% | -3.08% | -4.41% | -8.19% | 1.41% | -1.46% | -2.59% | -21.82% | -0.48% | -1.83% | -2.46% | -4% | 1.28% |
| EPS 2 | -0.0900 | -0.1400 | 0.002900 | -0.0500 | -0.0700 | -0.1400 | 0.0376 | -0.0400 | -0.0800 | -0.5700 | -0.0178 | -0.0686 | -0.0936 | -0.1557 | 0.0425 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 28/10/21 | 03/03/22 | 05/05/22 | 04/08/22 | 03/11/22 | 01/03/23 | 09/05/23 | 03/08/23 | 02/11/23 | 27/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 992 | 454 | 69 | 176 | 164 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -155 | -146 | -172 | -103 | -20 | -6.75 |
| ROE (net income / shareholders' equity) | - | -101% | -9.99% | -30.8% | -28.1% | -15.2% | -8.21% |
| ROA (Net income/ Total Assets) | - | -40% | -6.49% | -15.3% | -9.53% | -3.87% | - |
| Assets 1 | - | 1,016 | 1,642 | 1,719 | 1,530 | 2,118 | - |
| Book Value Per Share 2 | - | 2.730 | 2.520 | 1.600 | 1.380 | 1.230 | - |
| Cash Flow per Share 2 | - | -0.4000 | -0.3200 | -0.3800 | -0.0100 | -0.0500 | - |
| Capex 1 | - | 6.56 | 15.4 | 15.8 | 20.2 | 24.2 | 23.5 |
| Capex / Sales | - | 0.36% | 0.57% | 0.37% | 0.32% | 0.3% | 0.25% |
| Announcement Date | 18/03/21 | 03/03/22 | 01/03/23 | 27/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
4.96
USD
Average target price
8.441
USD
Spread / Average Target
+70.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.88% | 2.04B | |
| -18.60% | 3.01B | |
| -20.48% | 2.69B | |
| -27.31% | 317M | |
| +7.10% | 228M | |
| -46.75% | 176M | |
| -27.37% | 123M |
- Stock Market
- Equities
- AGL Stock
- Financials agilon health, inc.
